These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 32350699)

  • 1. LDL-Cholesterol-Lowering Therapy.
    Pirillo A; Norata GD; Catapano AL
    Handb Exp Pharmacol; 2022; 270():73-101. PubMed ID: 32350699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent insights into low-density lipoprotein metabolism and therapy.
    Pirillo A; Catapano AL; Norata GD
    Curr Opin Clin Nutr Metab Care; 2021 Mar; 24(2):120-126. PubMed ID: 33394716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapy: Guidelines to precision medicine.
    Su X; Cheng Y; Chang D
    Clin Chim Acta; 2021 Mar; 514():66-73. PubMed ID: 33359059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Sabatel-Pérez F; García-Ropero A; Santos-Gallego CG; Urooj Zafar M; Badimón JJ
    Drugs Today (Barc); 2019 May; 55(5):329-344. PubMed ID: 31131843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined lipid-lowering therapy.
    Karásek D
    Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein cholesterol lowering treatment: the current approach.
    Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC
    Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.